PRME NASDAQ
Prime Medicine, Inc.
1W: +11.0%
1M: +51.0%
3M: +43.6%
YTD: +23.2%
1Y: -18.4%
3Y: -39.1%
$4.35
+0.74 (+20.50%)
Weekly Expected Move ±16.7%
$2
$3
$4
$4
$5
Credit Risk of going bust: higher than 76% of companies Debt: 12.5% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the third-riskiest tenth, about 1 in 140 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.10 (down 98%), Prime Medicine, Inc. would be worth roughly what it owes.
Total debt $112.5M against a stock market value of $789.0M.
Distance to default 2.93 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $56.2M (short-term plus half of long-term), stock volatility 87.8%; Altman Z'' -15.98. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.10 (down 98%), Prime Medicine, Inc. would be worth roughly what it owes.
Total debt $112.5M against a stock market value of $789.0M.
Distance to default 2.93 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $56.2M (short-term plus half of long-term), stock volatility 87.8%; Altman Z'' -15.98. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
7 relationships7
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2024-02-16
Earliest Filing
2025-07-31
Latest Filing
partner: 6
customer: 1
Counterparties (Filed by PRME)
7 relationshipsCompanies named in PRME's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Cystic Fibrosis Foundation | — | customer | Purchased 1,818,181 shares of common stock | 2025-07-31 | View |
| Juno Therapeutics, Inc. | — | partner | Wholly-owned subsidiary of BMS that is a party to the Research Collaboration and License Agreement. | 2024-09-30 | View |
| Bristol-Myers Squibb Company | — | partner | Parent company of Juno Therapeutics; entered into a Research Collaboration and License Agreement and a Securities Purcha | 2024-09-30 | View |
| The Broad Institute, Inc. | — | partner | Licensee in the Broad-Prime License Agreement; entered into an amendment to modify obligations related to the collaborat | 2024-09-30 | View |
| Jefferies LLC | JEF | partner | Underwriter for the public offering of common stock | 2024-02-16 | View |
| Cowen and Company, LLC | — | partner | Underwriter for the public offering of common stock | 2024-02-16 | View |
| BMO Capital Markets Corp. | — | partner | Underwriter for the public offering of common stock | 2024-02-16 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-06 | Earnings Release; Exhibits | View | |
| 2026-07-08 | Other Events | View | |
| 2026-06-08 | Shareholder Vote | View | |
| 2026-05-07 | Earnings Release; Exhibits | View | |
| 2026-04-16 | Officer/Director Change | View | |
| 2026-03-03 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2026-01-12 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-11-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-09-08 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-08-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-05 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-07-31 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-07-30 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View | |
| 2025-07-15 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-06-05 | Submission of Matters to a Vote of Security Holders; Financial Statements and Exhibits | View | |
| 2025-05-19 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Other Events; Fi | View | |
| 2025-05-08 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-18 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-02-28 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-01-13 | Regulation FD Disclosure; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR